Endometrial Cancer Trial, Recruiting NCT07281599 Sponsor: Qurasense Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT07281599
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 25 years old or older and still have their cervix.
  • People who have been referred for a colposcopy (a close-up examination of the cervix) following an abnormal Pap smear or HPV screening result.
  • People whose menstrual periods arrive on a regular cycle, roughly every 21 to 35 days.
  • People who own a smartphone, have an email address, and are able to read the Qvin app instructions in English.
  • People who are willing to sign an electronic consent form.
  • People who agree to use a condom for any vaginal intercourse or shared penetrative toy use — from the time the Q-Pad sample is collected until the colposcopy appointment — if a new sexual partner is involved during that time.

Who may not be able to join:

  • People who are pregnant or who think they may be pregnant.
  • People who are unwilling or unable to use the two Q-Pad collection pads and mail them back to the trial site (note: mailing costs are covered by the trial).
  • People who have had treatment for cervical pre-cancer (such as LEEP, cone biopsy, or ablation) within the past 12 months.
  • People who have already enrolled in this study, or who are currently participating in another cervical screening or HPV study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Blumenthal, MD, MPH

Phone: 833-367-7846

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Qurasense
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinical Performance vs Histology; Proportion of participants with at least one reportable device-related adverse event (ADE or SADE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov